2015年6月5日 · Patients with EGFR-mutant lung cancer develop acquired resistance to EGFR and mutant-selective EGFR tyrosine kinase inhibitors. Here, we show that cotargeting EGFR …

MEK inhibition in EGFR or ERBB2-driven cancers however is complicated, as it can lead to higher PI3K/AKT activation. This is because inactivated MEK no longer activates ERK, which …

2020年1月13日 · In this issue of Cancer Cell, Kurppa et al. demonstrated that a senescence-like state enables lung cancer cells to survive dual inhibition of EGFR and MEK. This was …

2017年2月1日 · Preliminary data demonstrate that the triplet therapy with combined inhibition of EGFR, BRAF and MEK resulted in a more efficient reduction of pERK levels in tumour …

Here we investigate the effectiveness of co-targeting EGFR and MEK using in vitro and in vivo models of EGFR inhibitor sensitive and resistant cancers. We demonstrate that this …

2009年3月15日 · Enhanced cytotoxicity is demonstrated in cell lines with and without EGFR mutations, including those harboring the T790M escape mutation. These findings support …

2021年12月1日 · Despite the promising initial anti-tumor efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), most advanced non-small-cell lung cancers …

2025年3月22日 · EGFR/PI3K single-molecule inhibitor MTX-531 showed high potency as monotherapy in HNSCC-derived PDX. Additional combination with MAPK or KRAS-G12C …

Combined treatment with MEKi, EGFR inhibitor (EGFRi) and PD-L1 inhibitor (PD-L1i) resulted in a marked inhibition of tumor growth in both models. These results suggest a strategy to …

2020年1月13日 · Kurppa et al. show that YAP activation mediates resistance to combined EGFR/MEK inhibition by inducing dormancy in non-small-cell lung cancer cells. Targeting the …